Heron Therapeutics (NASDAQ:HRTX) Upgraded at StockNews.com

StockNews.com upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a buy rating in a research report report published on Tuesday morning.

Separately, Needham & Company LLC restated a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Wednesday, December 4th.

Heron Therapeutics Price Performance

Shares of HRTX stock opened at $1.76 on Tuesday. The company’s fifty day moving average price is $1.49 and its two-hundred day moving average price is $1.92. The firm has a market capitalization of $267.70 million, a P/E ratio of -9.78 and a beta of 1.60. Heron Therapeutics has a 12 month low of $1.04 and a 12 month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $32.81 million during the quarter, compared to analyst estimates of $36.40 million. During the same quarter last year, the firm posted ($0.17) EPS. On average, sell-side analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current year.

Institutional Trading of Heron Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. Apeiron RIA LLC lifted its holdings in Heron Therapeutics by 7.8% during the 4th quarter. Apeiron RIA LLC now owns 262,542 shares of the biotechnology company’s stock worth $402,000 after buying an additional 19,000 shares during the last quarter. Capital Planning Advisors LLC increased its stake in Heron Therapeutics by 41.0% during the fourth quarter. Capital Planning Advisors LLC now owns 106,565 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 31,003 shares during the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth $76,000. Congress Park Capital LLC lifted its position in shares of Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock worth $3,757,000 after buying an additional 477,417 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Heron Therapeutics by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 154,487 shares during the period. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.